Partner with us:
We believe great science comes from working together.
Focus on R&D:
Asahi Kasei Pharma Corporation is focused on the discovery and development of new drugs that address unmet medical needs.
Recent News
- November 8, 2023
- Asahi Kasei Pharma and SBI Biotech announce start of Phase 1 study to evaluate AK1910 as a potential treatment for autoimmune diseases
- September 29, 2023
- Asahi Kasei Pharma files application for approval to manufacture and sell Cresemba™ Capsule 40 mg as additional formulation in Japan
- September 5, 2023
- Notice of Issuance of a Provisional Disposition Order on Patent Infringement against a Generic of “Teribone™ Injection”
- August 30, 2023
- Announcement of listing on the NHI drug price standard and marketing of Empaveli® Subcutaneous Injection 1080 mg in Japan
- June 30, 2023
- Result of NEDO Smart Cell Project leads to commercial product
Contributing to dyslipidemia testing through supply of material for in vitro diagnostic assays - May 24, 2023
- Announcement of listing on the NHI drug price standard and marketing of Doptelet® Tablet 20 mg in Japan
- March 15, 2023
- Announcement of listing on the NHI drug price standard and marketing of Cresemba™ Capsule 100 mg and Cresemba™ Intravenous Infusion 200 mg in Japan
- March 13, 2023
- Asahi Kasei Pharma announces the start of a Phase 1 study of next-generation, long-acting GLP-2 analog peptide apraglutide in Japan